Myrcludex B

DRUG4 trials

Sponsors

Hepatera Ltd.

Conditions

Chronic Hepatitis BChronic Hepatitis D InfectionChronic Hepatitis D Infection With Hepatitis BChronic Viral Hepatitis B With Delta-agent

Phase 1

Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

CompletedNCT02637999

Hepatera Ltd.Chronic Hepatitis D Infection

Start: 2014-02-13End: 2016-01-21Updated: 2018-04-13

Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

CompletedNCT02881008

Hepatera Ltd.Chronic Hepatitis B

Start: 2012-11-14End: 2014-10-04Updated: 2018-09-19

Phase 2

Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

CompletedNCT02888106

Hepatera Ltd.Chronic Viral Hepatitis B With Delta-agent

Start: 2016-04-30End: 2020-10-30Updated: 2021-04-30

A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D

CompletedNCT03546621

Hepatera Ltd.Chronic Hepatitis D Infection With Hepatitis B

Start: 2016-02-16End: 2018-01-31Updated: 2021-05-10

Related Papers

Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐<scp>IFNα</scp>‐2a as Treatment for Chronic Hepatitis Delta

Liver International2025-01-248 citations

Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48

Liver International2024-12-0810 citations

Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies

Journal of Hepatology2024-02-0833 citations

No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.

2023-04-2717 citations

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.

2022-09-1392 citations